Mammoth Biosciences, the company behind the world’s first CRISPR-based disease detection platform, announced $23 million in funding.
The funds will allow the company to build out its IP portfolio, expand the team, and develop an infrastructure for partners to build on Mammoth’s CRISPR platform, with a keen eye on pharmaceutical and agricultural partnerships.
CRISPR (an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats) is a family of DNA sequences in bacteria and archaea. The sequences contain snippets of DNA from viruses that have attacked the prokaryote. These snippets are used by the prokaryote to detect and destroy DNA from similar viruses during subsequent attacks. These sequences play a key role in a prokaryotic defense system, and form the basis of a technology known as CRISPR/Cas9 that effectively and specifically changes genes within organisms.
Headquartered in San Francisco (USA), Mammoth Biosciences is a biotech company that has developed the world’s first and only CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA.
The funding round comes not long after the company came out of stealth in April 2018. The company is co-founded by Stanford and UC Berkeley PhDs Trevor Martin (CEO), Ashley Tehranchi (CTO), Lucas Harrington, Janice Chen and CRISPR pioneer Jennifer Doudna.
The team harnessed the naturally evolved diversity of bacterial CRISPR systems. Using proprietary CRISPR technology licensed exclusively from the University of California, Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows fast, simultaneous detection of multiple conditions, in real time, both in the hospital and at home. This pioneering approach has the potential to significantly reduce healthcare spending by replacing the need for dedicated testing devices, while also increasing accessibility and ease-of-use.
Similar to how Apple’s iOS created a democratized platform for developers, Mammoth’s long-term vision is to provide a CRISPR-based platform on which Mammoth and partners can build an infinite number of tests, both within healthcare and also across industries such as agriculture, oil and gas, and forensics.
Growth of the platform is powered by Mammoth’s CRISPR protein discovery engine – technology that is poised to explore and uncover additional Cas systems and reveal an infinite number of future applications.
Mammoth is currently reviewing partnership requests from those interested in building on its CRISPR-based platform, and fielding job applications from those interested in joining its all-star team.